Forum Financial Management LP Cuts Stake in Takeda Pharmaceutical Co. $TAK

Forum Financial Management LP lowered its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 19.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,934 shares of the company’s stock after selling 22,390 shares during the quarter. Forum Financial Management LP’s holdings in Takeda Pharmaceutical were worth $1,421,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in Takeda Pharmaceutical by 3.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 22,088 shares of the company’s stock worth $341,000 after buying an additional 715 shares in the last quarter. Sage Rhino Capital LLC lifted its position in Takeda Pharmaceutical by 7.9% in the second quarter. Sage Rhino Capital LLC now owns 12,604 shares of the company’s stock valued at $195,000 after purchasing an additional 919 shares during the last quarter. Jackson Thornton Wealth Management LLC lifted its position in Takeda Pharmaceutical by 7.8% in the second quarter. Jackson Thornton Wealth Management LLC now owns 12,779 shares of the company’s stock valued at $192,000 after purchasing an additional 920 shares during the last quarter. Intelligence Driven Advisers LLC lifted its stake in Takeda Pharmaceutical by 7.2% in the second quarter. Intelligence Driven Advisers LLC now owns 14,535 shares of the company’s stock worth $225,000 after acquiring an additional 977 shares during the period. Finally, Ieq Capital LLC boosted its holdings in Takeda Pharmaceutical by 4.6% in the first quarter. Ieq Capital LLC now owns 22,222 shares of the company’s stock valued at $330,000 after acquiring an additional 981 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.1%

Shares of NYSE:TAK opened at $14.13 on Thursday. The stock has a market capitalization of $44.95 billion, a price-to-earnings ratio of 47.08 and a beta of 0.21. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The stock’s 50-day simple moving average is $14.78 and its two-hundred day simple moving average is $14.74. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.69.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TAK. Weiss Ratings reissued a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, October 14th. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Takeda Pharmaceutical has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.